MX388170B - Polimorfos de selinexor - Google Patents

Polimorfos de selinexor

Info

Publication number
MX388170B
MX388170B MX2017002013A MX2017002013A MX388170B MX 388170 B MX388170 B MX 388170B MX 2017002013 A MX2017002013 A MX 2017002013A MX 2017002013 A MX2017002013 A MX 2017002013A MX 388170 B MX388170 B MX 388170B
Authority
MX
Mexico
Prior art keywords
structural formula
crystalline forms
compound
selinexor
polymorphs
Prior art date
Application number
MX2017002013A
Other languages
English (en)
Other versions
MX2017002013A (es
Inventor
Brian Clinton Austad
David G Roe
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of MX2017002013A publication Critical patent/MX2017002013A/es
Publication of MX388170B publication Critical patent/MX388170B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a formas cristalinas del compuesto representado por la Formula estructural I y a composiciones que comprenden formas cristalinas del compuesto representado por la Formula estructural I descrita en la presente. Las formas cristalinas del compuesto de Formula estructural I y las composiciones que comprenden las formas cristalinas del compuesto de Formula estructural I proporcionadas en la presente, en particular, la Forma cristalina unica A, se pueden incorporar en composiciones farmaceuticas, las cuales se pueden utilizar para tratar varios trastornos asociados con la actividad de CRM1, incluido el cancer. En la presente tambien se describen metodos para preparar el compuesto de Formula estructural I y sus formas cristalinas unicas.
MX2017002013A 2014-08-15 2015-08-14 Polimorfos de selinexor MX388170B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038069P 2014-08-15 2014-08-15
PCT/US2015/045395 WO2016025904A1 (en) 2014-08-15 2015-08-14 Polymorphs of selinexor

Publications (2)

Publication Number Publication Date
MX2017002013A MX2017002013A (es) 2017-05-12
MX388170B true MX388170B (es) 2025-03-19

Family

ID=53969460

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017002013A MX388170B (es) 2014-08-15 2015-08-14 Polimorfos de selinexor
MX2021014128A MX2021014128A (es) 2014-08-15 2017-02-14 Polimorfos de selinexor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014128A MX2021014128A (es) 2014-08-15 2017-02-14 Polimorfos de selinexor.

Country Status (18)

Country Link
US (6) US10519139B2 (es)
EP (2) EP3180331B1 (es)
JP (3) JP6777626B2 (es)
KR (1) KR102608259B1 (es)
CN (3) CN107072992B (es)
AU (4) AU2015301484B2 (es)
CA (1) CA2957266A1 (es)
CO (1) CO2017001884A2 (es)
DK (1) DK3180331T3 (es)
EA (1) EA201790384A1 (es)
ES (1) ES2926377T3 (es)
IL (1) IL250328B (es)
MA (1) MA40254B1 (es)
MX (2) MX388170B (es)
SG (2) SG11201700789SA (es)
UA (1) UA123535C2 (es)
WO (1) WO2016025904A1 (es)
ZA (1) ZA201700880B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3333164T3 (pl) 2011-07-29 2023-12-18 Karyopharm Therapeutics Inc. Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania
EA036639B1 (ru) 2012-05-09 2020-12-02 Байоджен Ма Инк. Модуляторы ядерного транспорта и их применение
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
SMT201900184T1 (it) 2013-06-21 2019-05-10 Karyopharm Therapeutics Inc 1,2,4-triazoli come modulatori di trasporto nucleare e loro usi
CA2957266A1 (en) 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) * 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US10993943B2 (en) 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
CN113423468A (zh) * 2019-03-20 2021-09-21 庄信万丰股份有限公司 塞利尼索的共晶体形式
AU2020266170A1 (en) * 2019-05-01 2021-11-25 Karyopharm Therapeutics Inc. Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors
EP3968987A4 (en) * 2019-05-16 2022-10-26 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
EP4452525A1 (en) * 2021-12-20 2024-10-30 RTX Corporation Particle enhancement of ceramic matrix composites, method of manufacture thereof and articles comprising the same
CN116675677B (zh) * 2023-08-02 2023-09-26 中国林业科学研究院林产化学工业研究所 一种c8漆酚衍生物及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
DE69736775T2 (de) 1996-04-04 2007-08-23 Shionogi & Co., Ltd. Cephemverbindungen und medikamente die diese verbindungen enthalten
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
EP1360901A1 (en) 1996-04-25 2003-11-12 Nissan Chemical Industries, Limited 2,3-cyclic substituted derivatives of 3-hydroxyacrolein and 3-hydroxyacrylic acid as pesticides
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
KR100966749B1 (ko) 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
BRPI0515015A (pt) 2004-08-11 2008-07-01 Kyorin Seiyaku Kk derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
RU2418793C2 (ru) 2005-11-15 2011-05-20 Оцука Фармасьютикал Ко., Лтд. Соединение оксазола и фармацевтическая композиция
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
RU2435764C2 (ru) 2006-04-18 2011-12-10 Ниппон Кемифар Ко., Лтд. АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ
JP4999923B2 (ja) 2006-06-13 2012-08-15 中国科学院上海薬物研究所 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
JP2012532889A (ja) 2009-07-09 2012-12-20 クレッシェンド セラピューティクス、エルエルシー 創傷治療方法及び傷跡変性方法
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
WO2012099807A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
PL3333164T3 (pl) * 2011-07-29 2023-12-18 Karyopharm Therapeutics Inc. Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania
US9428490B2 (en) 2011-07-29 2016-08-30 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
EA036639B1 (ru) 2012-05-09 2020-12-02 Байоджен Ма Инк. Модуляторы ядерного транспорта и их применение
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
US10202366B2 (en) * 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
SMT201900184T1 (it) 2013-06-21 2019-05-10 Karyopharm Therapeutics Inc 1,2,4-triazoli come modulatori di trasporto nucleare e loro usi
US11567063B2 (en) * 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
WO2016005548A1 (en) 2014-07-11 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers
WO2016015597A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CA2957266A1 (en) 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
WO2017040311A1 (en) 2015-08-28 2017-03-09 The Trustees Of Columbia University In The City Of New York Systems and methods for matching oncology signatures
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en) * 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US10993943B2 (en) * 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation
CN106831731B (zh) 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
US20220178927A1 (en) 2019-03-27 2022-06-09 Karyopharm Therapeutics Inc. Biomarkers for selinexor
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
ES3001533T3 (en) 2019-12-06 2025-03-05 Bae Systems Plc Light source
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Also Published As

Publication number Publication date
AU2015301484A1 (en) 2017-03-02
US20230242516A1 (en) 2023-08-03
JP2020143144A (ja) 2020-09-10
JP7558310B2 (ja) 2024-09-30
CN111484483B (zh) 2023-05-26
EP3180331B1 (en) 2022-06-08
MA40254B1 (fr) 2022-09-30
AU2020203246B2 (en) 2021-09-16
AU2024202835A1 (en) 2024-05-23
US11807629B2 (en) 2023-11-07
CN111481553B (zh) 2023-09-01
JP2017527549A (ja) 2017-09-21
US11746102B2 (en) 2023-09-05
AU2021286266A1 (en) 2022-01-06
US20200283419A1 (en) 2020-09-10
US12371420B2 (en) 2025-07-29
US20220135545A1 (en) 2022-05-05
CN111481553A (zh) 2020-08-04
JP6777626B2 (ja) 2020-10-28
AU2020203246A1 (en) 2020-06-04
SG11201700789SA (en) 2017-02-27
CN107072992B (zh) 2020-03-10
JP7218323B2 (ja) 2023-02-06
US20230242517A1 (en) 2023-08-03
KR102608259B1 (ko) 2023-11-29
IL250328B (en) 2022-05-01
US20240208943A1 (en) 2024-06-27
AU2021286266B2 (en) 2024-02-01
MA40254A (fr) 2021-05-19
UA123535C2 (uk) 2021-04-21
AU2015301484B2 (en) 2020-02-20
ZA201700880B (en) 2020-01-29
WO2016025904A1 (en) 2016-02-18
CA2957266A1 (en) 2016-02-18
IL250328A0 (en) 2017-03-30
US11753401B2 (en) 2023-09-12
US20180215733A1 (en) 2018-08-02
EA201790384A1 (ru) 2017-08-31
KR20170043561A (ko) 2017-04-21
DK3180331T3 (da) 2022-09-12
ES2926377T3 (es) 2022-10-25
JP2023052622A (ja) 2023-04-11
MX2017002013A (es) 2017-05-12
MX2021014128A (es) 2022-01-04
CN111484483A (zh) 2020-08-04
US10519139B2 (en) 2019-12-31
SG10201808624VA (en) 2018-11-29
CN107072992A (zh) 2017-08-18
CO2017001884A2 (es) 2017-07-19
EP4112615A1 (en) 2023-01-04
EP3180331A1 (en) 2017-06-21
NZ728850A (en) 2024-03-22
US11078190B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
MX388170B (es) Polimorfos de selinexor
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
MX376122B (es) Composiciones de plinabulina.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX376283B (es) Compuestos de imidazopiridazina.
PH12017500089A1 (en) Aldosterone synthase inhibitors
BR112017009289A2 (pt) métodos de administrar composições de amantadina
PH12017500595A1 (en) Aldosterone synthase inhibitors
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA033342B1 (ru) Пирролидинкарбоксамидо производные и способы их получения и их применение
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
EA201591449A1 (ru) Способы получения противораковых композиций
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12015502703A1 (en) Pharmaceutical compositions
NZ767083A (en) Polymorphs of selinexor
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
IN2014MU00070A (es)
EA201691191A1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона